Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Shire beats Street, restructures

Shire (LSE:SHP; SHPGY) reported second quarter earnings per ADS of $0.38, beating the Street estimate by a penny and up 10% quarter over quarter.

Read the full 248 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE